Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced that the last patient has been randomized in Cohort 2 of the ADX71149 Phase 2 epilepsy clinical study.
Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced that the last patient has been randomized in Cohort 2 of the ADX71149 Phase 2 epilepsy clinical study.